| Leigh Anne Savaiinaea, OTR/L | |
|
800 Ravenhill Dr, Atchison, KS 66002-9204 | |
| (913) 360-5537 | |
| Not Available |
| Full Name | Leigh Anne Savaiinaea |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 800 Ravenhill Dr, Atchison, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780459297 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 17-02072 (Kansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Leigh Anne Savaiinaea, OTR/L 800 Ravenhill Dr, Atchison, KS 66002-9204 Ph: (913) 360-5537 | Leigh Anne Savaiinaea, OTR/L 800 Ravenhill Dr, Atchison, KS 66002-9204 Ph: (913) 360-5537 |
News Archive
Offering your spouse what you believe to be positive support could have negative physiological effects on them, according to new research from Binghamton University, State University of New York.
New research from the University of Minnesota College of Veterinary Medicine has uncovered the role gene ORMDL3 plays in the disease asthma. ORMDL3, a gene recently linked to asthma susceptibility, has now been linked to the body's ability to recruit inflammatory cells during an airway allergic reaction. Study findings appear today in the journal Nature Communications.
The initial success rates of the most durable surgery for a common condition in women declines over the long-term, according to data published today in the Journal of the American Medical Association.
Nearly one quarter of women are likely to be victims of sexual assault in their lifetime. Now, a new project funded by Women's College Research Institute will examine the risk of sex assault for women who attend mass gatherings like concerts or sporting events.
BioDelivery Sciences International, Inc. announced that the company has been granted a meeting with the U.S. Food and Drug Administration (FDA) to discuss the planned Investigational New Drug (IND) application for BDSI's antiemetic (anti-nausea and vomiting) product candidate, BEMA Granisetron. The meeting will take place on March 17, 2010. The company will discuss with the FDA clinical development and regulatory plans for BEMA Granisetron, which is anticipated to enter Phase 1 studies in the second quarter of 2010.
› Verified 4 days ago
Wendy Marie Campbell, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 800 Ravenhill Dr, Atchison, KS 66002 Phone: 913-360-5550 | |
Megan Neill, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1419 N 6th St, Atchison, KS 66002 Phone: 913-367-1906 | |
Brooke Eckert, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1419 N 6th St, Atchison, KS 66002 Phone: 913-367-1906 | |
Sarah Johnston, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1637 Riley St, Atchison, KS 66002 Phone: 615-896-6400 |